Accession Number: | 0000899243-23-003896 |
Date: | 2023-02-01 |
Issuer: | AKERO THERAPEUTICS, INC. (AKRO) |
Original Submission Date: |
CHENG ANDREW
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO, CA 94080
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2023-02-01 | M | 25,000 | a | $0.62 | 395,999 | direct | ||
COMMON STOCK | 2023-02-01 | S | 14,845 | d | $48.57 | 381,154 | direct | ||
COMMON STOCK | 2023-02-01 | S | 8,155 | d | $49.67 | 372,999 | direct | ||
COMMON STOCK | 2023-02-01 | S | 2,000 | d | $50.14 | 370,999 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 0.615 | 2023-02-01 | deemed execution date | M | 25,000 (d) | 2028-10-17 | common stock 25,000 | $0.62 | 160,868 | direct |
ID | footnote |
---|---|
f1 | the reported transaction was effected pursuant to a rule 10b5-1 trading plan dated november 14, 2022, previously adopted by the reporting person. |
f2 | the price reported in column 4 is a weighted-average price. these shares were sold in multiple transactions at prices ranging from $48.03 to $49.01, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this form 4. |
f3 | the price reported in column 4 is a weighted-average price. these shares were sold in multiple transactions at prices ranging from $49.045 to $50.04, inclusive. |
f4 | the price reported in column 4 is a weighted-average price. these shares were sold in multiple transactions at prices ranging from $50.06 to $50.31, inclusive. |
f5 | the options are vested and currently exercisable. |